Recombinant Fibrinogen Like Protein 1 (FGL1)
FGL-1; HFREP1; HP-041; LFIRE1; Hepassocin; Hepatocyte-derived fibrinogen-related protein 1; Liver fibrinogen-related protein 1
- Product No.RPD022Hu01
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- SourceProkaryotic expression
- HostE.coli
- Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
- Subcellular LocationSecreted
- Predicted Molecular Mass40.7KDa
- Accurate Molecular Mass41kDa(Analysis of differences refer to the manual)
- Residues & TagsLeu23~Ile312 with N-terminal His Tag
- Buffer FormulationPBS, pH7.4, containing 0.01% SKL.
- Traits Freeze-dried powder
- Purity> 90%
- Isoelectric Point5.5
-
Applications
Positive Control; Immunogen; SDS-PAGE; WB.
If bio-activity of the protein is needed, please check active protein. - DownloadInstruction Manual
- UOM 10µg50µg 200µg 1mg 5mg
- FOB
US$ 168
For more details, please contact local distributors! US$ 420 US$ 840 US$ 2520 US$ 6300
SEQUENCE
USAGE
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
STORAGE
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
- Endotoxin Removal Kit
- BCA Protein Quantification Kit
- Protein Labeling Customized Service
- Molecular Mass Marker for Protein
- Recombinant Protein Customized Service
- Monoclonal Antibody Customized Service
- Polyclonal Antibody Customized Service
- Protein Activity Test Experiment Service
- Immunoprecipitation (IP) Experiment Service
- Buffer
- Endotoxin Removal Kit II
- Real Time PCR Experimental Service
- Spike RBD Protein (S-RBD)
- Protein G
- Protein A
Magazine | Citations |
J Hepatol. | The role of Hepassocin in the development of non-alcoholic fatty liver disease Pubmed: 23792031 |
Diabetes Management | Serum hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver disease Futuremedicine:Source |
United States Patent Application | Compositions and Methods for Diagnosing Lung Cancer y2016:0077095.html |
Cell | Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC Doi: 10.1016/j.cell.2018.09.053 |
Liver Research | Do different bariatric surgery procedures impact hepassocin plasma levels in patients with type 2 diabetes mellitus? |
Impacts of Different Modes of Bariatric Surgery on Plasma Levels of Hepassocin in Patients with Diabetes Mellitus |